90923-75-4

Basic information

• Product Name: 1-METHYL-1H-INDOLE-5-CARBALDEHYDE
• Synonyms: 1-METHYL-1H-INDOLE-5-CARBOXALDEHYDE;1-METHYL-1H-INDOLE-5-CARBALDEHYDE;1H-Indole-5-carboxaldehyde, 1-methyl- (9CI);1-Methyl-1H-indole-5-carboxaldehyde 97%;1-methyl-1H-indole-5-carbaldehyde(SALTDATA: FREE);5-Formyl-1-methyl-1H-indole;1-Methylindolecarbaldehyde;1-Methyl-1H-indole-5-carboxaldehyde97%
• CAS NO: 90923-75-4
• Molecular Formula: C₁₀H₉NO
• Molecular Weight: 159.18
• Product Categories: ALDEHYDE
• Mol File: 90923-75-4.mol
• Article Data: 26

Chemical Properties

• Melting Point: 84-85.5
• Boiling Point: 318.7°C at 760 mmHg
• Flash Point: 146.5°C
• Appearance: /Solid
• Density: 1.1g/cm³
• Vapor Pressure: 0.000356mmHg at 25°C
• Refractive Index: 1.585
• Storage Temp.: 2-8°C
• Sensitive: Air & Moisture Sensitive
• CAS DataBase Reference: 1-METHYL-1H-INDOLE-5-CARBALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-METHYL-1H-INDOLE-5-CARBALDEHYDE(90923-75-4)
• EPA Substance Registry System: 1-METHYL-1H-INDOLE-5-CARBALDEHYDE(90923-75-4)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-20/21/22
• Safety Statements: 26-36
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 90923-75-4(Hazardous Substances Data)

Usage

General Description

1-METHYL-1H-INDOLE-5-CARBALDEHYDE is a chemical compound with the molecular formula C10H9NO. It is an aromatic aldehyde with a methyl group and an indole ring, making it a heterocyclic compound. This chemical is commonly used in organic synthesis and pharmaceutical research as a building block to create various indole derivatives. It is also a key intermediate in the production of various drugs and agrochemicals. Additionally, 1-METHYL-1H-INDOLE-5-CARBALDEHYDE has been studied for its potential biological activities, including its anticancer, antibacterial, and antioxidant properties. Overall, this chemical compound has important applications in the fields of chemistry, pharmacology, and agrochemicals.

InChI:InChI=1/C10H9NO/c1-11-5-4-9-6-8(7-12)2-3-10(9)11/h2-7H,1H3

Upstream product

• 1196-69-6 1H-indole-5-carboxaldehyde 
• 74-88-4 methyl iodide 
• 280563-07-7 1-methyl-5-iodoindole 
• 10075-52-2 5-bromo-1-methyl-H-indole 
• 15226-74-1 dicobalt octacarbonyl 
• 60082-02-2 1-methylindoline-5-carboxaldehyde 
• 91459-39-1 1-Methyl-5-(trans-2-phenyl-1-ethenyl)indole 
• 108-98-5 thiophenol 
• 27064-03-5 S-phenyl methanethioate 
• 119072-55-8 tert-butylisonitrile 
• 68-12-2 N,N-dimethyl-formamide 
• 616-38-6 carbonic acid dimethyl ester 

Downstream Products

• 709649-73-0 N-methyl-1-(1-methyl-1H-indol-5-yl)methanamine 
• 1013932-69-8 1-methyl-2-phenyl-1H-indole-5-carbaldehyde 
• 1177251-50-1 5-[(1-benzyl-1H-tetrazol-5-yl)(4-cyclobutyl-1,4-diazepan-1-yl)methyl]-1-methyl-1H-indole 
• 1338778-09-8 4-(1-methyl-1H-indol-5-yl)-[1,3]dithiol-2-one 
• 61640-21-9 5-ethynyl-1-methyl-1H-indole 
• 448967-90-6 (1-methyl-1H-indol-5-yl)methanol 

Relevant articles and documents

Discovery of novel pyrazoline derivatives containing methyl-1H-indole moiety as potential inhibitors for blocking APC-Asef interactions

A series of novel pyrazoline derivatives containing methyl-1H-indole moiety were discovered as potential inhibitors for blocking APC-Asef interactions. The top hit Q19 suggested potency of inhibiting APC-Asef interactions and attractive preference for human-sourced colorectal cells. It was already comparable with the previous representative and the positive control Regorafenib before further pharmacokinetic optimization. The introduction of methyl-1H-indole moiety realized the Mitochondrial affection thus might connect the impact on the protein-interaction level with the apoptosis events. The molecular docking simulation inferred that bringing trifluoromethyl groups seemed a promising approach for causing more key interactions such as H-bonds. This work raised referable information for further discovery of inhibitors for blocking APC-Asef interactions.

COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS

The present invention relates to compounds of Formula (Ia) or pharmaceutically acceptable salts, hydrates, solvates, clathrates, polymorphs, stereoisomers thereof. It further discloses a pharmaceutical composition comprising compounds of Formula (Ia) and the use of compounds of Formula (Ib), in particular for the use in the treatment of diseases or disorders wherein disrupting Rad51-BRCA2 interaction is beneficial.

Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib

Synthetic lethality is an innovative framework for discovering novel anticancer drug candidates. One example is the use of PARP inhibitors (PARPi) in oncology patients with BRCA mutations. Here, we exploit a new paradigm based on the possibility of triggering synthetic lethality using only small organic molecules (dubbed "fully small-molecule-induced synthetic lethality"). We exploited this paradigm to target pancreatic cancer, one of the major unmet needs in oncology. We discovered a dihydroquinolone pyrazoline-based molecule (35d) that disrupts the RAD51-BRCA2 protein-protein interaction, thus mimicking the effect of BRCA2 mutation. 35d inhibits the homologous recombination in a human pancreatic adenocarcinoma cell line. In addition, it synergizes with olaparib (a PARPi) to trigger synthetic lethality. This strategy aims to widen the use of PARPi in BRCA-competent and olaparib-resistant cancers, making fully small-molecule-induced synthetic lethality an innovative approach toward unmet oncological needs.